Another FXR agonist such as Tropifexor (LJN452), which is highly specific for FXR target genes in the liver and intestine, in small doses and with fewer systemic effects, is currently in phase II trials for NASH (NCT02855164) [159]. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.